2
|
Miyagishima KJ, Sharma R, Nimmagadda M, Clore-Gronenborn K, Qureshy Z, Ortolan D, Bose D, Farnoodian M, Zhang C, Fausey A, Sergeev YV, Abu-Asab M, Jun B, Do KV, Kautzman Guerin MA, Calandria J, George A, Guan B, Wan Q, Sharp RC, Cukras C, Sieving PA, Hufnagel RB, Bazan NG, Boesze-Battaglia K, Miller S, Bharti K. AMPK modulation ameliorates dominant disease phenotypes of CTRP5 variant in retinal degeneration. Commun Biol 2021; 4:1360. [PMID: 34887495 PMCID: PMC8660775 DOI: 10.1038/s42003-021-02872-x] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2020] [Accepted: 11/09/2021] [Indexed: 12/13/2022] Open
Abstract
Late-onset retinal degeneration (L-ORD) is an autosomal dominant disorder caused by a missense substitution in CTRP5. Distinctive clinical features include sub-retinal pigment epithelium (RPE) deposits, choroidal neovascularization, and RPE atrophy. In induced pluripotent stem cells-derived RPE from L-ORD patients (L-ORD-iRPE), we show that the dominant pathogenic CTRP5 variant leads to reduced CTRP5 secretion. In silico modeling suggests lower binding of mutant CTRP5 to adiponectin receptor 1 (ADIPOR1). Downstream of ADIPOR1 sustained activation of AMPK renders it insensitive to changes in AMP/ATP ratio resulting in defective lipid metabolism, reduced Neuroprotectin D1(NPD1) secretion, lower mitochondrial respiration, and reduced ATP production. These metabolic defects result in accumulation of sub-RPE deposits and leave L-ORD-iRPE susceptible to dedifferentiation. Gene augmentation of L-ORD-iRPE with WT CTRP5 or modulation of AMPK, by metformin, re-sensitize L-ORD-iRPE to changes in cellular energy status alleviating the disease cellular phenotypes. Our data suggests a mechanism for the dominant behavior of CTRP5 mutation and provides potential treatment strategies for L-ORD patients.
Collapse
Affiliation(s)
- Kiyoharu J. Miyagishima
- grid.280030.90000 0001 2150 6316Section on Epithelial and Retinal Physiology and Disease, NEI, NIH, Bethesda, MD 20892 USA
| | - Ruchi Sharma
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Malika Nimmagadda
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Katharina Clore-Gronenborn
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Zoya Qureshy
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Davide Ortolan
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Devika Bose
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Mitra Farnoodian
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Congxiao Zhang
- grid.280030.90000 0001 2150 6316Section on Epithelial and Retinal Physiology and Disease, NEI, NIH, Bethesda, MD 20892 USA
| | - Andrew Fausey
- grid.280030.90000 0001 2150 6316Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD 20892 USA
| | - Yuri V. Sergeev
- grid.280030.90000 0001 2150 6316Ophthalmic Genetics and Visual Function Branch, National Eye Institute, NIH, Bethesda, MD 20892 USA
| | - Mones Abu-Asab
- grid.280030.90000 0001 2150 6316Section of Histopathology, National Eye Institute, NIH, Bethesda, MD 20892 USA
| | - Bokkyoo Jun
- grid.279863.10000 0000 8954 1233Neuroscience Center of Excellence, Louisiana State University Health, New Orleans, LA 70112 USA
| | - Khanh V. Do
- grid.279863.10000 0000 8954 1233Neuroscience Center of Excellence, Louisiana State University Health, New Orleans, LA 70112 USA
| | - Marie-Audrey Kautzman Guerin
- grid.279863.10000 0000 8954 1233Neuroscience Center of Excellence, Louisiana State University Health, New Orleans, LA 70112 USA
| | - Jorgelina Calandria
- grid.279863.10000 0000 8954 1233Neuroscience Center of Excellence, Louisiana State University Health, New Orleans, LA 70112 USA
| | - Aman George
- grid.280030.90000 0001 2150 6316Ophthalmic Genetics and Visual Function Branch, National Eye Institute, NIH, Bethesda, MD 20892 USA
| | - Bin Guan
- grid.280030.90000 0001 2150 6316Medical Genetics and Ophthalmic Genomics Unit, NEI, NIH, Bethesda, MD 20892 USA
| | - Qin Wan
- grid.280030.90000 0001 2150 6316Section on Epithelial and Retinal Physiology and Disease, NEI, NIH, Bethesda, MD 20892 USA
| | - Rachel C. Sharp
- grid.25879.310000 0004 1936 8972Department of Biochemistry University of Pennsylvania, 240 South 40th Street, Levy Building, Room 515, Philadelphia, PA 19104 USA
| | - Catherine Cukras
- grid.280030.90000 0001 2150 6316Division of Epidemiology and Clinical Applications and Ophthalmic Genetics and Visual Function Branch, NEI, NIH, Bethesda, MD 20892 USA
| | - Paul A. Sieving
- grid.280030.90000 0001 2150 6316Section for Translation Research in Retinal and Macular Degeneration, NEI, NIH, Bethesda, MD 20892 USA
| | - Robert B. Hufnagel
- grid.280030.90000 0001 2150 6316Medical Genetics and Ophthalmic Genomics Unit, NEI, NIH, Bethesda, MD 20892 USA
| | - Nicolas G. Bazan
- grid.279863.10000 0000 8954 1233Neuroscience Center of Excellence, Louisiana State University Health, New Orleans, LA 70112 USA
| | - Kathleen Boesze-Battaglia
- grid.25879.310000 0004 1936 8972Department of Biochemistry University of Pennsylvania, 240 South 40th Street, Levy Building, Room 515, Philadelphia, PA 19104 USA
| | - Sheldon Miller
- grid.280030.90000 0001 2150 6316Section on Epithelial and Retinal Physiology and Disease, NEI, NIH, Bethesda, MD 20892 USA
| | - Kapil Bharti
- Ocular and Stem Cell Translational Research Section, NEI, NIH, Bethesda, MD, 20892, USA.
| |
Collapse
|
3
|
Rugolo F, Bazan NG, Calandria J, Jun B, Raschellà G, Melino G, Agostini M. The expression of ELOVL4, repressed by MYCN, defines neuroblastoma patients with good outcome. Oncogene 2021; 40:5741-5751. [PMID: 34333551 DOI: 10.1038/s41388-021-01959-3] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2021] [Revised: 06/30/2021] [Accepted: 07/12/2021] [Indexed: 02/07/2023]
Abstract
Cancer cells exhibit dysregulation of critical genes including those involved in lipid biosynthesis, with subsequent defects in metabolism. Here, we show that ELOngation of Very Long chain fatty acids protein 4 (ELOVL4), a rate-limiting enzyme in the biosynthesis of very-long polyunsaturated fatty acids (n-3, ≥28 C), is expressed and transcriptionally repressed by the oncogene MYCN in neuroblastoma cells. In keeping, ELOVL4 positively regulates neuronal differentiation and lipids droplets accumulation in neuroblastoma cells. At the molecular level we found that MYCN binds to the promoter of ELOVL4 in close proximity to the histone deacetylases HDAC1, HDAC2, and the transcription factor Sp1 that can cooperate in the repression of ELOVL4 expression. Accordingly, in vitro differentiation results in an increase of fatty acid with 34 carbons with 6 double bonds (FA34:6); and when MYCN is silenced, FA34:6 metabolite is increased compared with the scrambled. In addition, analysis of large neuroblastoma datasets revealed that ELOVL4 expression is highly expressed in localized clinical stages 1 and 2, and low in high-risk stages 3 and 4. More importantly, high expression of ELOVL4 stratifies a subsets of neuroblastoma patients with good prognosis. Indeed, ELOVL4 expression is a marker of better overall clinical survival also in MYCN not amplified patients and in those with neuroblastoma-associated mutations. In summary, our findings indicate that MYCN, by repressing the expression of ELOVL4 and lipid metabolism, contributes to the progression of neuroblastoma.
Collapse
Affiliation(s)
- Francesco Rugolo
- Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy
| | - Nicolas G Bazan
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA
| | - Jorgelina Calandria
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA
| | - Bokkyoo Jun
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, New Orleans, LA, USA
| | - Giuseppe Raschellà
- Laboratory of Health and Environment, Italian National Agency for New Technologies, Energy and Sustainable Economic Development (ENEA), Rome, Italy
| | - Gerry Melino
- Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy.
| | - Massimiliano Agostini
- Department of Experimental Medicine, TOR, University of Rome Tor Vergata, Rome, Italy.
| |
Collapse
|
4
|
Pham TL, He J, Kakazu AH, Calandria J, Do KV, Nshimiyimana R, Lam TF, Petasis NA, Bazan HEP, Bazan NG. ELV-N32 and RvD6 isomer decrease pro-inflammatory cytokines, senescence programming, ACE2 and SARS-CoV-2-spike protein RBD binding in injured cornea. Sci Rep 2021; 11:12787. [PMID: 34140611 PMCID: PMC8211643 DOI: 10.1038/s41598-021-92293-x] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2020] [Accepted: 06/04/2021] [Indexed: 12/31/2022] Open
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) has resulted in a pandemic affecting the most vulnerable in society, triggering a public health crisis and economic collapse around the world. Effective treatments to mitigate this viral infection are needed. Since the eye is a route of virus entrance, we use an in vivo rat model of corneal inflammation as well as human corneal epithelial cells (HCEC) in culture challenged with IFNγ as models of the eye surface to study this issue. We explore ways to block the receptor-binding domain (RBD) of SARS-CoV-2 Spike (S) protein to angiotensin-converting enzyme 2 (ACE2). We found that the lipid mediators, elovanoid (ELV)-N32 or Resolvin D6-isomer (RvD6i) decreased the expression of the ACE2 receptor, furin, and integrins in damaged corneas or IFNγ-stimulated HCEC. There was also a concomitant decrease in the binding of Spike RBD with the lipid treatments. Using RNA-seq analysis, we uncovered that the lipid mediators also attenuated the expression of pro-inflammatoy cytokines participating in hyper-inflammation and senescence programming. Thus, the bioactivity of these lipid mediators will contribute to open therapeutic avenues to counteract virus attachment and entrance to the body.
Collapse
Affiliation(s)
- Thang L Pham
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA
| | - Jiucheng He
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA
| | - Azucena H Kakazu
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA
| | - Jorgelina Calandria
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA
| | - Khanh V Do
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA
| | - Robert Nshimiyimana
- Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA, USA
| | - Ting F Lam
- Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA, USA
| | - Nicos A Petasis
- Department of Chemistry and Loker Hydrocarbon Research Institute, University of Southern California, Los Angeles, CA, USA
| | - Haydee E P Bazan
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA.
| | - Nicolas G Bazan
- Neuroscience Center of Excellence, School of Medicine, Louisiana State University Health New Orleans, 2020 Gravier St., Ste. D, New Orleans, LA, 70112-2223, USA.
| |
Collapse
|
5
|
Pham TL, He J, Kakazu AH, Calandria J, Do KV, Nshimiyimana R, Petasis NA, Bazan HEP, Bazan NG. Elovanoid-N32 or RvD6-isomer decrease ACE2 and binding of S protein RBD after injury or INFγ in the eye. Res Sq 2020:rs.3.rs-55764. [PMID: 32818210 PMCID: PMC7430585 DOI: 10.21203/rs.3.rs-55764/v1] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection that causes coronavirus disease 2019 (COVID-19) has resulted in a pandemic affecting the most vulnerable in society, triggering a public health crisis and economic tall around the world. Effective treatments to mitigate this virus infection are needed. Since the eye is a route of virus entrance, we use an in vivo rat model of corneal inflammation as well as human corneal epithelial cells in culture challenged with IFNγ to study this issue. We explore ways to block the receptor-binding domain (RBD) of SARS-CoV-2 spike (S) protein to angiotensin-converting enzyme 2 (ACE2). Elovanoid (ELV)-N32 or Resolvin D6-isomer (RvD6i), among the lipid mediators studied, consistently decreased the expression of the ACE2 receptor, furin, and integrins in damaged corneas or IFNγ stimulated human corneal epithelial cells (HCEC). There was also a concomitant decrease in the binding of spike RBD with the lipid treatments. Concurrently, we uncovered that the lipid mediators also attenuated the expression of cytokines that participate in the cytokine storm, hyper-inflammation and senescence programming. Thus, the bioactivity of these lipid mediators will contribute to opening therapeutic avenues for COVID-19 by counteracting virus attachment and entrance to the eye and other cells and the ensuing disruptions of homeostasis.
Collapse
Affiliation(s)
| | - Jiucheng He
- Louisiana State University Health New Orleans
| | | | | | - Khanh V Do
- Louisiana State University Health New Orleans
| | | | | | | | | |
Collapse
|